Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Mar 24, 2025
Initial data for AlloNK® from autoimmune program expected H1 2025
Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025
Read more at globenewswire.comNASDAQ:ARTV (10/10/2025, 9:10:34 PM)
2.81
-0.19 (-6.33%)
Find more stocks in the Stock Screener
